VIP - Vasoactive Intestinal Peptide

🔹 What is VIP (Vasoactive Intestinal Peptide)?

Class: Endogenous neuropeptide—28-amino-acid peptide naturally produced in the gut, brain, and immune cells. Mechanism: Binds VPAC1 and VPAC2 receptors to regulate vasodilation, smooth muscle relaxation, and hormone secretion (e.g., insulin, glucagon). Modulates immune responses, supports gut motility, and enhances microcirculation. May influence cognition and tissue repair indirectly via vascular and metabolic effects. Primary focus: Vasodilation, immune modulation, gut health, metabolic support, hormone regulation, potential tissue repair, and circulatory enhancement.

---

🔹 Oral Dosage (least common) Range studied/used in research: Oral bioavailability is extremely low; peptide is rapidly degraded in the GI tract. Typical protocol: No established oral dosing; subcutaneous, intravenous, or intranasal routes are required for systemic effects. Notes: Oral administration is largely ineffective; stability and absorption issues prevent meaningful systemic activity.

---

🔹 Injectable / Sublingual / Intranasal Dosage (most common) Range: Commonly used in research at 25–100 µg per dose subcutaneously or intranasally, 1–2 times daily. Clinical trials and anecdotal protocols occasionally use up to 200 µg/day depending on goal. Frequency: Typically 1–2 times daily; dosing can be adjusted based on therapeutic target, gut health, or circulatory support. Rationale: Direct administration ensures vascular and tissue access, supporting vasodilation, immune modulation, and gut functionality.

---

🔹 Cycle Length Common cycle length: 4–8 weeks is common in anecdotal and research contexts. Off-cycle: 2–4 week breaks may be implemented to assess efficacy, prevent receptor desensitization, or reduce tolerance. Note: Duration is based on experimental data and user reports; formal long-term protocols are not well-established.

---

🔹 Optimal Dosing Window Injectable / Sublingual / Intranasal: Morning or early afternoon is preferred for metabolic and circulatory support. Evening dosing is generally avoided due to potential interference with circadian hormone patterns or sleep.

---

✅ Educational Integration Example (injectable / intranasal) Example protocol: 50 µg subcutaneous or intranasal dose once daily at 9 AM for 6 weeks. Pair with: Cardiovascular exercise, hydration, and gut-supportive nutrition to maximize circulatory and metabolic benefits.

---

🔹 Stacking Strategy (Educational) Since VIP primarily targets vasodilation, gut health, and immune modulation, stacking focuses on supporting circulation, metabolism, and tissue repair: 🔸 Circulatory & Metabolic Support

• AOD-9604: Complementary fat metabolism and lipid regulation.
• L-Carnitine: Supports mitochondrial fat oxidation and energy.

🔸 Recovery & Tissue Support

• BPC-157 or TB-500: Support connective tissue and gut repair, synergizing with VIP’s tissue-protective effects.
• Collagen peptides: Aid vascular and musculoskeletal support.

🔸 Longevity / Immune & Gut Optimization

• NAD⁺ precursors (NMN/NR): Support cellular repair and immune resilience.
• Gut microbiome support (prebiotics/probiotics): Enhance VIP-mediated gut and immune benefits.

Disclaimer: Do not rely on any dosing information provided, this is for educational and research only. Always double and triple check alternative references for education. Please consult with healthcare provider for your specific dosing and protocol if applicable.